The following content is translated from Chinese source by machine translation without post-editing.
Recently, Ms. Su Yang, General Manager of TalkingChina, was invited to attend an industry exchange event hosted by French Healthcare. Under the theme of “2025 China Pharmaceutical and Medical Device Market Review & 2026 Outlook”, the event brought together numerous experts and enterprise representatives from the medical and healthcare sectors of China and France.
The event was moderated by Mr. Eric BOUTEILLER, Adjunct Professor at China Europe International Business School (CEIBS). Mr. Eric Shao, Vice President and General Manager of Commercial Solutions for IQVIA Greater China, served as the keynote speaker. The guests delivered in-depth presentations on core topics including the structural changes in China’s pharmaceutical and medical device market, policy drivers, the far-reaching impact of volume-based procurement, the landscape of innovative R&D, and the accelerated progress of domestic substitution.
Ms. Su’s participation in this event aimed to gain in-depth insights into the latest developments and policy trends in China’s pharmaceutical and healthcare market, further enhancing TalkingChina’s industry expertise and service capabilities in the healthcare sector.
China’s pharmaceutical market is undergoing a transition from “high-speed growth” to “high-quality development”, driven by the dual engines of cost control and innovation. Domestic enterprises are rising rapidly, while multinational corporations are facing new challenges and opportunities. Against this backdrop, precise language communication and localization services have become critical support for Chinese and foreign enterprises to smoothly access the market, understand policies, and carry out cooperation.
As a professional language service provider with years of in-depth experience in the industry, TalkingChina has long upheld the mission of “helping local enterprises go global and overseas enterprises enter the Chinese market”.We maintain a focused presence in key sectors including pharmaceuticals, medical devices, law, finance, IT, and manufacturing, offering a comprehensive portfolio of services: multilingual solutions for global expansion, interpretation and equipment support, translation and localization, transcreation and copywriting, as well as film and video translation.Our language capabilities cover more than 80 languages worldwide, including English, Japanese, Korean, French, German, Spanish, and Portuguese.
In terms of translation strength, since 2015, TalkingChina has built a comprehensive network of native-speaking translators for both Chinese foreign and English foreign language pairs. We have carefully selected more than 2,000 contracted translators worldwide, covering specialized fields including medicine, pharmacy, clinical practice, regulatory affairs and more.
The company possesses professional expertise in handling high demand documents such as drug registration dossiers, clinical trial protocols, medical device instructions, and GMP certification documentation. We also provide long term simultaneous and consecutive interpretation services for well known pharmaceutical enterprises, medical institutions, and industry forums both at home and abroad.
Backed by a strict quality management system and industry expert validation, TalkingChina ensures that every deliverable is accurate, professional and compliant, effectively helping clients reduce language risks and communication costs in international business cooperation.
Looking ahead, TalkingChina will continue to leverage its strong translation team and extensive industry experience to deepen its presence in the healthcare sector, contributing linguistic support to the connectivity between China and the global pharmaceutical and medical device markets.
Post time: Apr-13-2026